Magle Chemoswed Holding AB (“Magle Chemoswed”) today announces that Magle Chemoswed Holding AB and its subsidiary Magle Biopharma AB (together, the “Licensors”) have entered into an exclusive license agreement (the “Agreement”) with Aktiebolaget Grundstenen 178422 which has applied for a name change to Alvion Bio AB (“Alvion Bio”), granting Alvion Bio exclusive worldwide rights to develop and commercialise the Group’s amniotic stem cell technology.
Alvion Bio has been established for the sole purpose of developing and commercialising the licensed technology and is owned by Justin Pierce, former Chief Executive Officer of Magle Group.
Under the Agreement, Alvion Bio will assume full responsibility for the continued development, regulatory advancement, and commercialisation of the licensed technology within the defined field.
The Agreement is not expected to have a material impact on Magle Chemoswed’ s financial results in 2026 but is expected to reduce operating costs by approximately SEK10 million and may generate future royalty revenue.
The licensed technology comprises intellectual property, know-how, cell lines, manufacturing processes, data, and related materials associated with amniotic stem cell–derived products. Alvion Bio has been established specifically to continue development activities and pursue regulatory approval and commercialisation of therapeutic products based on the licensed technology.
As part of the transaction:
“This agreement represents an important strategic milestone for Magle Group. It enables a structured exit from the amniotic stem cell field while preserving long-term value potential through royalties and participation in future commercial success. At the same time, it allows us to sharpen our focus on our core business and strategic priorities,” said Aaron Wong, interim CEO of Magle Chemoswed Holding AB.
The Agreement was entered into on 28 February 2026, and becomes effective immediately.